International Livestock Research Institute (ILRI), Nairobi, Kenya.
Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA, USA.
Transbound Emerg Dis. 2020 Mar;67 Suppl 1:88-98. doi: 10.1111/tbed.13417.
The live infection and treatment (ITM) vaccination procedure using the trivalent Muguga cocktail is increasingly being used to control East Coast fever, with potential implications for Theileria parva population genetic structure in the field. Transmission of the Kiambu V T. parva component to unvaccinated cattle has previously been described in Uganda. We monitored the T. parva carrier state in vaccinated and control animals on a farm in West Kenya where an ITM stabilate derived from the Kenyan T. parva Marikebuni stock was evaluated for field efficacy. A nested PCR-based Marikebuni-specific marker identified a carrier state in nine of ten vaccinated animals, detectable for a period of two years. We used 22 variable number tandem repeat (VNTR) markers to determine multilocus genotypes (MLGs) of 19 T. parva schizont-infected lymphocyte isolates derived from cattle and field ticks. Two isolates from unimmunized cattle were identical to the Marikebuni vaccination stock. Two cattle isolates were identical to a Muguga cocktail component Kiambu V. Seven isolates from ticks exhibited MLGs that were identical to the Serengeti/Muguga vaccine stocks. Six cattle and two tick-derived stocks exhibited unique MLGs. The data strongly suggest transmission of immunizing genotypes, from Marikebuni vaccine-induced carrier cattle to unimmunized cattle. It is possible that genotypes similar to those in the Muguga cocktail are present in the field in Western Kenya. An alternative hypothesis is that these parasites may have originated from vaccine trial sites in Eastern Uganda. If correct, this suggests that T. parva stocks used for immunization can potentially be disseminated 125 km beyond the immediate vaccination site. Regardless of their origin, the data provide evidence that genotypes similar to those in the Muguga cocktail are circulating in the field in East Africa, alleviating concerns about dissemination of 'alien' T. parva germplasm through live vaccination.
使用三价 Muguga 鸡尾酒进行活体感染和治疗 (ITM) 接种程序,正越来越多地用于控制东非昏睡病,这可能对现场的 Theileria parva 种群遗传结构产生影响。此前,在乌干达已经描述了 Kiambu V T. parva 成分向未接种疫苗的牛传播。我们在肯尼亚西部的一个农场监测了接种和对照动物的 T. parva 携带状态,在那里评估了源自肯尼亚 T. parva Marikebuni 株的 ITM 稳定株的田间功效。基于嵌套 PCR 的 Marikebuni 特异性标记在十只接种动物中的九只中检测到了携带状态,可检测到两年。我们使用 22 个可变数串联重复 (VNTR) 标记来确定源自牛和田间蜱的 19 个 T. parva 裂殖子感染淋巴细胞分离株的多位点基因型 (MLG)。来自未免疫牛的两个分离株与 Marikebuni 疫苗株完全相同。两个牛分离株与 Muguga 鸡尾酒成分 Kiambu V 相同。从蜱中分离出的七个分离株表现出与 Serengeti/Muguga 疫苗株相同的 MLG。六个牛和两个蜱衍生株表现出独特的 MLG。数据强烈表明,来自 Marikebuni 疫苗诱导的携带牛的免疫基因型已传播给未免疫的牛。在肯尼亚西部的野外,可能存在类似于 Muguga 鸡尾酒中的基因型。另一种假设是,这些寄生虫可能起源于乌干达东部的疫苗试验地点。如果正确,这表明用于免疫接种的 T. parva 株可能会在接种点以外 125 公里的范围内传播。无论其来源如何,这些数据都提供了证据,表明类似于 Muguga 鸡尾酒中的基因型正在东非野外循环,减轻了通过活体接种传播“外来” T. parva 种质的担忧。